Artificial intelligence is reshaping Pharmaceutical research and development, regulatory affairs, and clinical operations at a pace that few industries have previously experienced. From AI-accelerated drug discovery and predictive Clinical Trial design to...

Drug approval is the beginning of a Pharmaceutical company's regulatory obligation — not its culmination. Once a product receives marketing approval, an extensive and ongoing set of post-marketing requirements comes into effect:...

For Indian Pharmaceutical manufacturers with ambitions to supply regulated international markets - the United States, European Union, United Kingdom, Canada, and Australia — obtaining and maintaining approval from international regulatory authorities is...

In Pharmaceutical development, time is capital. Every month of delay between trial design and first patient enrolled has a quantifiable cost - in direct operational expenditure, in foregone revenue from delayed commercialisation,...

Why India's Regulatory System is Different For companies entering India with Biological products for the first time, one of the most frequent surprises is the multiplicity of Regulatory authorities involved in approval,...

The revision of Schedule M to India's Drugs and Cosmetics Act represents one of the most consequential regulatory changes for domestic Pharmaceutical manufacturers in recent memory. Notified by the Ministry of Health...

For global Pharmaceutical companies evaluating emerging market expansion, three regions consistently dominate strategic discussions: India, ASEAN, and the GCC. Each offers compelling growth characteristics. Each carries a distinct regulatory architecture, commercial structure,...

Pharmaceutical acquisitions are complex, high-stakes transactions. Financial modelling, commercial valuation, and market positioning typically receive the most intensive scrutiny. Yet the most consequential risks in many transactions are neither financial nor commercial...